Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA appropriation stalls

This article was originally published in The Tan Sheet

Executive Summary

The House Appropriations Committee postpones a markup of fiscal 2011 agriculture funding legislation, leaving FDA funding in limbo. The House adjourned for August recess without taking action, leaving fiscal 2011 funding levels undetermined until Congress returns the week of Sept. 13. With all House members and some of the Senate soon to focus on elections, chances are growing for an omnibus bill or continuing resolution to fund federal agencies at the start of the next fiscal year (1"The Tan Sheet" July 26, 2010)

You may also be interested in...



FDA Funding Not Set As Chances Grow For Omnibus Or Continuing Resolution

FDA's fiscal 2011 funding is not the only decision Congress has yet to make - lawmakers likely will face passing either an omnibus spending bill or a continuing resolution to keep the federal government operating past the end of the current fiscal year

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS104357

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel